Loïc Badé will join Bayer Leverkusen if nothing goes wrong in the coming hours, according to Spanish journalist Alejandro Sáez. Fabrizio Romano also notes that Badé is very close to leaving Sevilla ...

Kumquat, based in San Diego, received US Food and Drug Administration clearance of its investigational new drug application for the KRAS G12D inhibitor in July. The firm will be responsible for ...

Serie A Defender on the RadarThe summer transfer window is always a pivotal time for football clubs, and Liverpool are ...

Small bands of Russian soldiers thrust deeper into eastern Ukraine on Tuesday ahead of a summit this week between Russian ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech company to develop its prospective cancer drug.

Today’s White House MAHA Commission report is expected to pull punches on pesticide regulation as Bayer lobbies to limit ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

An offer is yet to be made for the England international while an agreement would also need to be reached on the player side.

Ernest Poku has officially joined Bayer 04 Leverkusen from Dutch side AZ.The 21-year-old winger has inked a five-year deal ...

Bayer Leverkusen sporting director Simon Rolfes said of the club’s new acquisition: “Ernest is an excellent winger who, with ...

Bayer (BAYZF) on Tuesday unveiled a partnership deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.